Northwest Biotherapeutics (NWBO) Share-based Compensation (2010 - 2026)

Northwest Biotherapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $288000.0 for Q1 2026.

• In Q1 2026, Share-based Compensation fell 25.19% year-over-year to $288000.0; the TTM figure through Mar 2026 stood at $1.1 million (up 367.47% YoY), while the FY2025 annual figure was $1.2 million, up 231.59% from the prior year.
• Share-based Compensation for Q1 2026 stood at $288000.0, up from $185000.0 in the prior quarter.
• The five-year high for Share-based Compensation was $5.8 million in Q2 2022, with the low at -$2.0 million in Q3 2024.
• The 5-year median for Share-based Compensation is $775000.0 (2022), against an average of $1.2 million.
• Peak annual rise in Share-based Compensation reached 314.75% in 2024, while the deepest fall reached 220.41% in 2024.
• Northwest Biotherapeutics' Share-based Compensation stood at $2.6 million in 2022, then slumped by 38.4% to $1.6 million in 2023, then sank by 224.0% to -$2.0 million in 2024, then jumped by 109.47% to $185000.0 in 2025, then soared by 55.68% to $288000.0 in 2026.
• Business Quant data shows NWBO's Share-based Compensation at $288000.0 in Q1 2026, $185000.0 in Q4 2025, and $273000.0 in Q3 2025.